

# Chaochen Wang

Outcomes Research Manager, Bayer Yakuhin, Ltd

✉ [chaochen.wang1@alumni.lshtm.ac.uk](mailto:chaochen.wang1@alumni.lshtm.ac.uk) 🌐 [wangcc.me](http://wangcc.me) | Updated: December 24, 2025

## EDUCATION

|   |        |
|---|--------|
| <b>London School of Hygiene &amp; Tropical Medicine</b> , MSc of Medical Statistics, Distinction Degree | 2018.9 |
| <b>Nagoya University Graduate School of Medicine</b> , PhD in Public Health                             | 2016.3 |
| <b>Nagoya University Graduate School of Medicine</b> , Master of Medical Science in Epidemiology        | 2013.3 |
| <b>Shanghai Jiaotong University</b> , B.S. Nutrition Science  | 2010.7 |

## AWARDS & SCHOLARSHIPS

|   |           |
|---|-----------|
| <b>Outstanding Graduates of Shanghai Jiaotong University</b>  | 2010      |
| Recipient of <b>Ajinomoto Scholarship</b> for outstanding students from overseas  | 2011-2012 |
| <b>Young Investigator's Award</b> , The 48th Annual Meeting of the Japanese Society of Cardiovascular Disease Prevention, Tokyo | 2012      |
| Recipient of scholarship from <b>Otsuka Toshimi Scholarship Foundation</b>  | 2013-2014 |
| <b>Best Reviewer</b> of Journal of Epidemiology   | 2021.1.28 |
| <b>Lilly Japan 2024Q2 President Award winner</b>  | 2024      |
| <b>Lilly Japan Innovator Award</b>  | 2024      |

- Innovative machine learning approach in Japan real world effectiveness study for RA patients.
- Using SNS data to reveal Atopic dermatitis patients' unmet needs for future personalized treatment strategy
- Promoting innovative readiness from the early phase of development of Lp(a): evidence from large-scale epidemiological study in Japan.

## LANGUAGES

- Chinese Mandarin: Native Speaker
- Chinese Hokkien: Native Speaker
- English: Fluent (IELTS overall: 8; L 8.5, R 8.5, W 7, S 7) - 2017.1.7
- Japanese: Advanced (Japanese Language Proficiency Level 1)

## CAREER HISTORY

**Integrated Evidence Generation (IEG), Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd**

Outcomes Research Manager 2025.7–Present

**Japan Value, Evidence and Outcomes (VEO), Japan Drug Development and Medical Affairs (JDD&MA), Eli Lilly and Company Japan K.K.**

Principal Scientist 2024.3–2025.6

**Japan Value, Evidence and Outcomes (VEO), Japan Drug Development and Medical Affairs (JDD&MA), Eli Lilly and Company Japan K.K.**

Senior Scientist 2021.10–2024.3

*Responsibility: Real world evidence (RWE) planning and generation*

- Develops and oversees local RWE strategy for Lilly's products in Japan in immunology, CVD and oncology area
- Answering data queries from internal clients (marketing/pricing/clinical development/medical affairs etc.) using commercially available databases: Medical Data Vision, JMDC Claims database, etc.
- Lead in proposing, designing, and execution of observational researches generate RWE to support compounds from early clinical development throughout the whole life cycle.
- Key member of Lilly Japan's internal real world related working groups of
  - Integrated data platform for diverse RWD/E utilization
  - Scientific study design
  - Real-world data analytics
- Attended the VEO International Meeting in the UK (2024/04/14 - 2024/04/21) on behalf of Eli Lilly Japan VEO scientists, exchanging knowledge with Chinese and European colleagues and presenting our experiences on research collaborations with Public Interest Association and academic institutions

**Department of Public Health, Aichi Medical University School of Medicine:**

Assistant Professor

2015.4–2021.9

*Responsibility: teaching and research*

- Working closely with the professors and other colleagues mainly in epidemiology of gastroenterological cancer
- Responsible for statistical consulting from medical doctors in the university hospital
- Responsible for education to undergraduate medical students on statistical methods used in medical researches
- Cooperating with medical doctors in hospital university on projects studying locomotive syndrome

*Projects:*

- Data analysis using large scale cohort studies such as the Japan Collaborative Cohort Study, literature meta-analysis, the UK National Diet and Nutrition Survey Rolling Program data, and data provided by doctors in Aichi Medical University hospital
- All projects and publications were conducted under Linux environment such as Ubuntu OS with R, STATA, and/or Python language
- Presented in the World Congress of Epidemiology in Alaska (2014) as well as in Saitama (2017) as poster presentations
- Research on the day-time patterns of carbohydrate intake using the UK national Diet and Nutrition Survey data was accepted as oral presentation in the 13th European Nutrition Conference in Dublin, Ireland 2019

**Nagoya University Graduate School of Medicine - Department of Public Health and Health Systems**

Visiting Faculty

*Responsibility:*

- Provide lectures/seminars (topics include advanced statistical methodology such as Causal Inference) to graduate students in the Department of Public Health and Health Systems

**Clinical Study Support:**

Part-time Researcher (8h/w)

2018.10–2021.6

*Responsibility: statistical analysis, training of the analysis team*

- Experience in producing statistical analysis plan (SAP) for clinical and observational studies; conducted detailed comparisons and results calculation on cancer survival from hospital clients; performed database analyses through commercial medical databases such as Medical Database Vision.

- Organizing statistical study seminars to train the team members and learn the latest statistical knowledge and skills for on-going and future study projects

## PUBLICATIONS:

(while in Eli Lilly):

- \*Wang, C., Aranishi, T., Reed, C., Anderson, P., Austin, J., Davis, V. A., Quinones, E., & Piercy, J. (2022). Impact of Patient and Physician Disconnect on Satisfaction with Treatment for Atopic Dermatitis in Japan. *Dermatology and Therapy*. <https://doi.org/10.1007/s13555-022-00866-z>
- Maruyama, D., \*Wang, C., Y. Tanizawa, Z. Cai, Y. Huang, M. Tajimi and S. Kusumoto (2023). "Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study." *J Clin Exp Hematop* 63(4): 219-229.
- \*Wang, C., T. Ishizuka, M. Tanaka, K. Matsuo, H. Knight, N. Harvey, L. Gillespie-Akar and T. H. Gibble (2023). "Bowel Urgency in Patients with Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Real-World Survey in Japan." *Adv Ther*.
- \*Wang, C., H. Torisu-Itakura, T. Hanada, T. Matsuo, Z. Cai, S. Osaga and T. Aranishi (2023). "Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study." *Journal of Dermatological Treatment* 34(1).
- Kagawa, Y., \*Wang, C., Y. Piao, L. Jin, Y. Tanizawa, Z. Cai and Y. Sunakawa (2024). "Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study." *Target Oncol*.
- Otsuka, A., \*Wang, C., H. Torisu-Itakura, T. Matsuo, Y. Isaka, P. Anderson, J. Piercy, J. Austin, S. Marwaha and A. Tanaka (2024). "Patient and family burden in pediatric atopic dermatitis and its treatment pattern in Japan." *Int J Dermatol*.
- Yuda, J., \*Wang, C., T. Terasawa, M. Tajimi, S. Osaga, M. Miura, S. Takaoka and Y. Tanizawa (2024). "Treatment selection and influencing factors for chronic lymphocytic leukemia: a physician survey in Japan." *Int J Clin Oncol*.
- Nishino, K., \*Wang, C., S. Mizuno, N. Sekine, Y. Tanizawa, Z. Cai and K. Nakamura (2024). "Real-world Evidence of Skin Disorder-related Events Management in Patients with Lung Cancer Prescribed the RELAY Regimen (Erlotinib Plus Ramucirumab) - A Retrospective Observational Study Using A Health Insurance Claims Database in Japan [Article in Japanese]." *J. New Rem. & Clin.* 73: 7.
- Lipoprotein(a) levels and the risk of coronary heart disease and stroke: the Suita Study. *Journal of Atherosclerosis and Thrombosis*. 2025 (accepted for publication, this is a collaborative study between Lilly and National Cerebral and Cardiovascular Center)

More Publications before joining Eli Lilly can be found from [ORCID 0000-0001-5533-1497](#)